Samaraweera Amal P R, Cohen Stuart N, Akay Ela M, Evangelou Nikos
Division of Clinical Neuroscience, Queen's Medical Centre, University of Nottingham, UK.
Nottingham University Hospitals NHS Trust, UK.
Mult Scler. 2016 Jan;22(1):122-4. doi: 10.1177/1352458515597568. Epub 2015 Jul 28.
Fingolimod was the first oral disease-modifying treatment for relapsing-remitting multiple sclerosis. It has previously been associated with the development of lymphoma.
To describe a case of lymphomatoid papulosis, a CD30+ cutaneous lymphoproliferative disorder, in a patient taking fingolimod.
Case study.
Our patient developed lymphomatoid papulosis 2 months after starting fingolimod. Histology confirmed the diagnosis. The drug was withdrawn. Resolution began only 2 days later.
Lymphomatoid papulosis is a benign subtype of cutaneous T-cell lymphoma, but up to 20% of cases can transform to a malignant course. Patients on fingolimod and physicians caring for them should be mindful of the need to monitor the skin.
芬戈莫德是第一种用于复发缓解型多发性硬化症的口服疾病修正治疗药物。它此前曾与淋巴瘤的发生有关。
描述1例服用芬戈莫德的患者发生淋巴瘤样丘疹病（一种CD30 +皮肤淋巴细胞增殖性疾病）的病例。
病例研究。
我们的患者在开始服用芬戈莫德2个月后发生淋巴瘤样丘疹病。组织学检查确诊。停用该药物。仅2天后病情开始缓解。
淋巴瘤样丘疹病是皮肤T细胞淋巴瘤的一种良性亚型，但高达20%的病例可转变为恶性病程。服用芬戈莫德的患者及其主治医生应注意监测皮肤情况。
